"The success of TULSA represents a revolution in whole-gland treatment forprostate cancer," said lead author Steven S. Raman, M.D., FASR, FSIR, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA. "Prostate cancer is the most common form of cancer ...
Molecular mechanisms contributing to the pathogenesis of prostate cancer progression and castration resistance have been the target for developing novel therapeutic options to improve survival and quality of life for patients with mCRPC. These emerging agents include androgen synthesis inhibitors, androgen ...
CHICAGO, June 30 (Xinhua) -- The situation of limited treatment options for men with non-metastatic castrate-resistant prostate cancer and a quickly rising prostate-specific antigen (PSA) level may be broken. A study by researchers at Northwestern University (NU) Medicine shows that a drug curre...
300 men in the U.S. in 2023, according to American Cancer Society estimates. For some, treatment may never be needed because they have a slow-growing form of the disease, but those with moreaggressive prostate cancerare often first treated with surgery orradiation therapy....
New therapy modalities for the treatment of advanced prostate cancer based on peptide analogues are reviewed. Results Agonists and antagonists of luteinising hormone-releasing hormone (LHRH) lead to androgen deprivation, but direct effects on tumours may also play a role. Radiolabeled somatostatin analog...
Kumar, MD, professor of medicine, Mayo Clinic Comprehensive Cancer Center, highlighted new treatment options for patients with multiple myeloma, including chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. Callander noted how CAR-T cell therapies and bispecific engagers have ...
The safety of second-line treatment options for non-small cell lung cancer Non-small-cell lung cancer (NSCLC) patients after first-line therapy ultimately suffer progression. At this time, many patients still have a good performan... A Rossi,P Maione,G Santabarbara,... - 《Expert Opinion ...
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib...
Treatment Options in Hormone-Refractory Prostate Cancer Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced prostate cancer is suppre... KA Harris,DM Reese - 《Drugs》 被引量: 117发表: 2001年 加载更多来源...
death among men in the United States. Metastatic, castrate-resistantprostate cancer(mCRPC) is an incurable form of prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Researchers are looking for new treatment options to use for ...